AcNK-Sup003 cell therapy for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests a new immune cell treatment called AcNK-Sup003 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior therapy. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and expected to live more than 3 months.
- You have a type of B-cell lymphoma that is CD20-positive and has come back or not responded to at least two prior treatments, including a CD20-targeted drug and an anthracycline chemotherapy.
- You have at least one measurable tumor (lymph node >15 mm or other lesion >10 mm) seen on a PET scan.
- Your blood counts, kidney, liver, and lung function must meet certain minimum levels.
- You cannot have active central nervous system lymphoma, serious heart problems, active autoimmune disease, or uncontrolled infections.
- You must agree to use effective birth control for 6 months after the last treatment dose if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational cell therapy that targets two markers (CD20 and CD19) on your lymphoma cells. It may be an option if your B-cell lymphoma has come back or not responded to prior treatments.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This trial tests a personalized immune treatment made from your own NK cells (a type of blood-fighting immune cell) for relapsed or refractory B-cell non-Hodgkin lymphoma. It aims to check safety and whether the treatment can shrink lymphoma and help control the disease.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
This trial tests a new treatment using your own immune cells (called CAR-NK cells) that are trained to find and kill leukemia cells. It may be an option if your B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to previous treatments.
Hear when a new B-cell Non-Hodgkin Lymphoma (B-NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.